Mats Holmqvist

Novartis (Switzerland)

Papers

1

Total Citations

40

H-Index

1

About

Mats Holmqvist is a leading figure in the development of advanced electrophysiological tools for drug discovery, with a primary focus on ion channel pharmacology and microfluidic patch-clamp technology. His most cited work introduces the IonFlux system, a revolutionary microfluidic patch-clamp platform that dramatically enhances the throughput and predictive accuracy of ion channel assays. This innovation is critical for both identifying promising new therapeutic compounds and minimizing cardiotoxic side effects, particularly in the study of the human *Ether-à-go-go* Related Gene (hERG) channel—a key safety target in pharmaceutical development. With over 40 citations, Holmqvist’s 2011 study demonstrated the system’s ability to efficiently capture hERG channel physiology and pharmacology, offering a cost-effective and reliable alternative to traditional methods. His contributions have helped bridge the gap between high-throughput screening and physiological relevance, making him a pivotal researcher in the field of safety pharmacology and microfluidic bioengineering. Holmqvist’s work continues to influence how scientists approach ion channel drug safety testing.

Research Focus

Key Achievements

1
H-Index
1
Papers
40
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
IonFlux: A Microfluidic Patch Clamp System Evaluated with Human <i>Ether-à-go-go</i> Related Gene Channel Physiology and Pharmacology
40 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Novartis (Switzerland)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago